Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Genomische profilering bij kankerpatiënten

23 september 2026 bijgewerkt door: Memorial Sloan Kettering Cancer Center

The purpose of this study is to determine whether certain genes in cancer may be abnormal. When a gene is abnormal this is called a mutation. Most mutations in cancer cells are not inherited (passed down from parents) but happen after birth in the cancer itself. Most cancers have many mutations. Some of these mutations are important for the cancer cells to survive while others are not. The goal of this study is test cancer for certain mutations using leftover tumor tissue from a previous surgery or biopsy. Participants will also be asked to provide a tube of blood cheek (also known as a buccal) swab, or a saliva sample that contains normal genes for comparison.

The purpose of Part B of this study is to:

Understand how genetic changes in tumor effect the chance of responding to experimental cancer treatment. Understand how the genes in the tumor change overtime in response to targeted cancer treatment.

Studie Overzicht

Studietype

Observationeel

Inschrijving (Geschat)

200

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: David Solit, MD
  • Telefoonnummer: 646-888-2641

Studie Contact Back-up

  • Naam: Zsofia Stadler, MD
  • Telefoonnummer: 646-888-4039

Studie Locaties

    • Connecticut
      • Bridgeport, Connecticut, Verenigde Staten, 06606
        • Nog niet aan het werven
        • St. Vincent (Data Collection Only)
        • Contact:
          • Christopher Iannuzzi, MD
          • Telefoonnummer: 203-576-6000
      • Hartford, Connecticut, Verenigde Staten, 06102
        • Nog niet aan het werven
        • Hartford Healthcare Cancer Institute @ Hartford Hospital
        • Contact:
          • Andrew Salner, MD
          • Telefoonnummer: 860-972-2803
      • Norwalk, Connecticut, Verenigde Staten, 06850
        • Werving
        • Norwalk Hospital
        • Contact:
          • Linda Vahdat, MD
          • Telefoonnummer: 203-845-4811
    • Florida
      • Miami, Florida, Verenigde Staten, 33143
        • Werving
        • Baptist Alliance MCI
        • Contact:
          • John Diaz, MD
          • Telefoonnummer: 786-596-2000
    • New Jersey
      • Basking Ridge, New Jersey, Verenigde Staten, 07920
        • Werving
        • Memorial Sloan Kettering Basking Ridge
        • Contact:
          • David Solit, MD
          • Telefoonnummer: 646-888-2641
      • Middletown, New Jersey, Verenigde Staten, 07748
        • Werving
        • Memorial Sloan Kettering Monmouth
        • Contact:
          • David Solit, MD
          • Telefoonnummer: 646-888-2641
      • Montvale, New Jersey, Verenigde Staten, 07645
        • Werving
        • Memorial Sloan Kettering Bergen
        • Contact:
          • David Solit, MD
          • Telefoonnummer: 646-888-2641
    • New York
      • Brooklyn, New York, Verenigde Staten, 11203
        • Werving
        • Kings County Hopsital Center
        • Contact:
          • Jason Gonsky, MD
          • Telefoonnummer: 718-245-2847
      • Commack, New York, Verenigde Staten, 11725
        • Werving
        • Memorial Sloan Kettering Cancer Commack
        • Contact:
          • David Solit, MD
          • Telefoonnummer: 646-888-2641
      • Harrison, New York, Verenigde Staten, 10604
        • Werving
        • Memorial Sloan Kettering Westchester
        • Contact:
          • David Solit, MD
          • Telefoonnummer: 646-888-2641
      • Jamaica, New York, Verenigde Staten, 11432
        • Werving
        • Queens Cancer Center of Queens Hospital
        • Contact:
          • Debra Ferman, MD
          • Telefoonnummer: 718-579-6021
      • New York, New York, Verenigde Staten, 10065
        • Werving
        • Memorial Sloan Kettering Cancer Center
        • Contact:
          • David Solit, MD
          • Telefoonnummer: 646-888-2641
        • Contact:
          • Zsofia Stadler, MD
          • Telefoonnummer: 646-888-4039
        • Hoofdonderzoeker:
          • David Solit, MD
      • New York, New York, Verenigde Staten, 10029
        • Werving
        • Metropolitan Hospital Center
        • Contact:
          • Anitha Srinivasan, MD
          • Telefoonnummer: 212-423-6262
      • New York, New York, Verenigde Staten, 10035
        • Werving
        • Ralph Lauren Center for Cancer Care and Prevention
        • Contact:
          • Lewis P. Kampel, MD
          • Telefoonnummer: 646-422-4474
      • Richmond Hill, New York, Verenigde Staten, 11418
        • Werving
        • Medisys Health Network (Data Collection Only)
        • Contact:
          • Rosa Nouvini, MD
          • Telefoonnummer: 718-206-6000
      • The Bronx, New York, Verenigde Staten, 10451
        • Werving
        • NYC Health & Hospitals /Lincoln Medical Center
        • Contact:
          • Monica Reddy Muppidi, MD
          • Telefoonnummer: 718-579-4977
        • Hoofdonderzoeker:
          • Monica Reddy Muppidi, MD
      • Uniondale, New York, Verenigde Staten, 11553
        • Werving
        • Memorial Sloan Kettering Nassau
        • Contact:
          • David Solit, MD
          • Telefoonnummer: 646-888-2641
    • Pennsylvania
      • Allentown, Pennsylvania, Verenigde Staten, 18103
        • Werving
        • Lehigh Valley Health Network
        • Contact:
          • Suresh Nair, MD
          • Telefoonnummer: 610-402-7880

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Patients with solid or hematologic cancers who may be and considered potential candidates for a therapeutic protocol will be recruited to Part A of this study. Enrollment to therapeutic clinical trials will not be contingent on enrollment in this protocol.

Part B: Research Collection Cohort Patients potentially appropriate will be identified by their treating physician in each participating Disease Management Team.

Beschrijving

Inclusion Criteria:

Part A:

  • Patients with a history of cancer or patients without a documented cancer history undergoing a surgical procedure, endoscopy, biopsy, or liquid biopsy (for example cell free DNA testing) to confirm or exclude a cancer diagnosis, or
  • Any participant having a test or procedure that has the potential to provide a specimen that can be banked for future research purposes, or
  • Any participant who has already had a diagnostic or therapeutic procedure that has yielded tissue, blood or other bodily fluids presently in the archive but who has not yet been approached to participate is also eligible.

Part B:

  • Patients must be successfully registered to Part A of MSKCC IRB# 12-245
  • Prior written approval for patient consent obtained from the Principal/Co-Principal Investigator of MSKCC IRB # 12-245.

Part C:

  • Patient must be receiving ongoing care at MSK or a CHERPn/ Alliance/Affiliate site or have previously consulted with an MSK physician.
  • Patient must have successfully consented to Part A of this study.

Part D:

  • Patients with no personal cancer history at increased risk for cancer development due to family history, molecular cancer marker, know carrier status of a gene associated with increased cancer risk or prior/ongoing environmental exposures or lifestyle factors.

Exclusion Criteria:

All Parts:

  • Unwilling or unable to provide informed consent.

Part C:

  • All patients consenting to Part A are eligible to consent to 12-245, Part C. Most patients will be eligible to receive clinical germline testing with return of results to the patient/health care providers. However, several exclusion criteria apply and are outlined below

    1. Solid tumor patients: Secondary germline analysis using BAM files generated for MSK-IMPACT testing is not an option for patients with solid tumors and an acute or chronic hematologic neoplasm that would preclude the use of blood or saliva as a source of germline DNA. Such patient may be eligible for primary germline testing using a non-blood source of germline DNA as per standard clinical guidelines. Solid tumor patients who have had an allogenic bone marrow/stem cell transplant will only be considered eligible for germline testing under Part C if a sample adequate for germline testing had previously been collected prior to allogenic bone marrow/stem cell transplant.
    2. Hematologic cancer patients: For patients with a hematopoietic neoplasm, germline testing may be an option under Part C using nail clippings or another non-blood source of DNA as per standard clinical practice. For patients who have had an allogenic bone marrow/stem cell transplant, clinical germline testing will only be considered under Part C if a sample adequate for germline testing had previously been collected prior to Allogenic bone marrow/stem cell transplant.

Part D

  • Exclusion criteria are same as those for Part C outlined above.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Pts with solid tumors

Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.

Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational "next-generation" profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, & others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection & research biopsies.

Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the "ACMG list").

Part D: Germline Profiling for Individuals at Elevated Cancer Risk

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
frequency of "actionable" oncogenic mutations
Tijdsspanne: 1 year

"Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.

1 year

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To determine the impact of molecular profiling results performed in the CLIA-setting on the treatment of patients.
Tijdsspanne: 1 year

The Bioinformatics Core will assist in interpreting data generated by next-generation sequencing techniques such as WES and WGS.

1 year
interrogate the mechanisms
Tijdsspanne: 1 year

underlying response and resistance (de-novo and acquired) to targeted therapy. The research assay(s) used to accomplish this will vary based on the clinical setting and tissue available and may include Sanger, Sequenom, MiSeq, exon-capture (ie: IMPACT), whole exome, and whole genome sequencing.

1 year
To explore the genetic mechanisms of tumorigenesis
Tijdsspanne: 2

in a subset of specimens with no identifiable culpritic genomic alterations on highly-multiplexed next-generation sequencing (i.e.: IMPACT testing) by using even more comprehensive investigational profiling techniques such as whole exome sequencing, whole genome sequencing or RNA sequencing

2

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: David Solit, MD, Memorial Sloan Kettering Cancer Center

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 januari 2013

Primaire voltooiing (Geschat)

1 januari 2027

Studie voltooiing (Geschat)

1 januari 2027

Studieregistratiedata

Eerst ingediend

21 januari 2013

Eerst ingediend dat voldeed aan de QC-criteria

21 januari 2013

Eerst geplaatst (Geschat)

24 januari 2013

Updates van studierecords

Laatste update geplaatst (Werkelijk)

24 september 2026

Laatste update ingediend die voldeed aan QC-criteria

23 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren